Rivulet Media Inc (fka RIVU)

[GM_FSJ]

Although Regen BioPharma and Dr. Wei-Ping Min have previously published in the area of gene silencing, all work has been performed in animal studies. These are the first experiments in which human cells were utilized in a manner similar to which will be filed with the FDA. "We are optimistic that this data will lead to advancement of dCellVax into clinical trials," said David Koos, PhD, Chairman and CEO of Regen BioPharma. "The smooth translation of this university acquired intellectual property into a commercial setting further supports the Regen BioPharma model of rapidly advancing patents that are sitting un-noticed in the technology transfer offices of universities."